New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
05:13 EDTSNY, MNKDSanofi, MannKind announce global licensing agreement for Afrezza
Sanofi (SNY) and MannKind (MNKD) announced that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in 1Q15. Under the collaboration and license agreement, Sanofi will be responsible for global commercial, regulatory and development activities. Under a separate supply agreement, MannKind will manufacture Afrezza at its manufacturing facility in Danbury, Connecticut. In addition, the companies are planning to collaborate to expand manufacturing capacity to meet global demand as necessary. Under the terms of the agreement, MannKind will receive an upfront payment of $150M and potential milestone payments of up to $775M. The milestone payments are dependent upon specific regulatory and development targets, as well as sales thresholds. Sanofi and MannKind will share profits and losses on a global basis, with Sanofi retaining 65% and MannKind receiving 35%. Sanofi has agreed to advance to MannKind its share of the collaboration's expenses up to a limit of $175M.
News For SNY;MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
08:01 EDTSNYAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTSNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
05:54 EDTMNKDStocks with implied volatility above IV index mean; MNKD AMBA
Subscribe for More Information
August 26, 2015
05:52 EDTMNKDStocks with implied volatility movement; TSM MNKD
Subscribe for More Information
August 20, 2015
11:33 EDTSNYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
09:47 EDTMNKDMannKind failed to settle loan by deadline, TheStreet's Feuerstein says
Subscribe for More Information
August 19, 2015
11:01 EDTMNKDStocks with call strike movement; MNKD SUNE
MannKind (MNKD) November 4.5 call option implied volatility increased 3% to 81, SunEdison (SUNE) January 16 call option implied volatility decreased 1% to 73 according to IVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use